Jeff J Subleski

Summary

Affiliation: National Cancer Institute
Country: USA

Publications

  1. pmc Application of tissue-specific NK and NKT cell activity for tumor immunotherapy
    Jeff J Subleski
    Cancer and Inflammation Program, National Cancer Institute, 1050 Boyles Street, Frederick, MD 21702, USA
    J Autoimmun 33:275-81. 2009
  2. pmc TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells
    Jeff J Subleski
    Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
    J Immunol 186:838-47. 2011
  3. pmc Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment
    Jonathan M Weiss
    Laboratory of Experimental Immunology, Cancer and Inflammation Program, NCI Frederick, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 106:19455-60. 2009
  4. pmc The split personality of NKT cells in malignancy, autoimmune and allergic disorders
    Jeff J Subleski
    Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institute of Health, Frederick, MD 21702, USA
    Immunotherapy 3:1167-84. 2011
  5. pmc Immunotherapy of cancer by IL-12-based cytokine combinations
    Jonathan M Weiss
    National Cancer Institute, Cancer and Inflammation Program, Laboratory of Experimental Immunology, Center for Cancer Research, Frederick, MD 21702, USA
    Expert Opin Biol Ther 7:1705-21. 2007
  6. ncbi request reprint Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver
    Jeff J Subleski
    Laboratory of Experimental Immunology, Science Applications International Corporation Frederick, National Cancer Institute Center for Cancer Research, Frederick, Maryland, USA
    Cancer Res 66:11005-12. 2006
  7. pmc Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias
    Deborah L Hodge
    Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute Frederick, and SAIC Frederick, Frederick, Maryland 21702 1201, USA
    Cancer Res 69:3986-94. 2009
  8. ncbi request reprint Peroxisome proliferator-activated receptor-gamma and its ligands attenuate biologic functions of human natural killer cells
    Xia Zhang
    Laboratory of Experimental Immunology, Center for Cancer Reseach, National Cancer Institute Frederick, National Institutes of Health, Frederick, MD 21702 1201, USA
    Blood 104:3276-84. 2004
  9. ncbi request reprint The proinflammatory cytokine interleukin-18 alters multiple signaling pathways to inhibit natural killer cell death
    Deborah L Hodge
    Laboratory of Experimental Immunology, Center for Cancer Research, National Cancer Institute Frederick, Frederick, MD 21702 1201, USA
    J Interferon Cytokine Res 26:706-18. 2006

Collaborators

  • Howard A Young
  • John R Ortaldo
  • Jun Yang
  • Xiao Ming Yin
  • Xin Chen
  • Yili Yang
  • Deborah L Hodge
  • Jonathan M Weiss
  • Robert H Wiltrout
  • Matthew D Buschman
  • Della A Reynolds
  • Xia Zhang
  • William Bere
  • Jimmy K Stauffer
  • Kory Alderson
  • William J Murphy
  • Paul M Schaughency
  • Hong Dang
  • Veronica L Hall
  • Anthony J Scarzello
  • Thomas P Loughran
  • Ram Savan
  • Dejan Micic
  • Timothy C Back
  • Jon M Wigginton
  • Anatoli M Malyguine
  • William B Schill
  • Mark W Burkett
  • Ji Ming Wang
  • Osamu Shimozato
  • Maria Cecilia Rodriguez-Galan

Detail Information

Publications9

  1. pmc Application of tissue-specific NK and NKT cell activity for tumor immunotherapy
    Jeff J Subleski
    Cancer and Inflammation Program, National Cancer Institute, 1050 Boyles Street, Frederick, MD 21702, USA
    J Autoimmun 33:275-81. 2009
    ..The unique properties and roles as critical effector cells make NK and NKT cells within the liver microenvironment attractive targets of immunotherapeutic approaches that have the goal of controlling tumor metastasis in the liver...
  2. pmc TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells
    Jeff J Subleski
    Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
    J Immunol 186:838-47. 2011
    ..Additionally, TCR-dependent and -independent activation differentially regulate iNKT cell distribution and phenotype. These results provide new insights for understanding how iNKT cells are systemically regulated following activation...
  3. pmc Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment
    Jonathan M Weiss
    Laboratory of Experimental Immunology, Cancer and Inflammation Program, NCI Frederick, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 106:19455-60. 2009
    ..These results suggest that the use of anti-CD40 in combination with IL-2 or IL-15 may hold substantially more promise for clinical cancer treatment than anti-CD40 alone...
  4. pmc The split personality of NKT cells in malignancy, autoimmune and allergic disorders
    Jeff J Subleski
    Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institute of Health, Frederick, MD 21702, USA
    Immunotherapy 3:1167-84. 2011
    ..We also examine the growing evidence that NKT cells are involved in liver inflammatory conditions that can contribute to the development of malignancy...
  5. pmc Immunotherapy of cancer by IL-12-based cytokine combinations
    Jonathan M Weiss
    National Cancer Institute, Cancer and Inflammation Program, Laboratory of Experimental Immunology, Center for Cancer Research, Frederick, MD 21702, USA
    Expert Opin Biol Ther 7:1705-21. 2007
    ....
  6. ncbi request reprint Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver
    Jeff J Subleski
    Laboratory of Experimental Immunology, Science Applications International Corporation Frederick, National Cancer Institute Center for Cancer Research, Frederick, Maryland, USA
    Cancer Res 66:11005-12. 2006
    ..These results suggest that immunotherapeutic approaches that enhance NK cell function while eliminating or altering NKT cells could be effective in the treatment of cancer in the liver...
  7. pmc Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias
    Deborah L Hodge
    Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute Frederick, and SAIC Frederick, Frederick, Maryland 21702 1201, USA
    Cancer Res 69:3986-94. 2009
    ....
  8. ncbi request reprint Peroxisome proliferator-activated receptor-gamma and its ligands attenuate biologic functions of human natural killer cells
    Xia Zhang
    Laboratory of Experimental Immunology, Center for Cancer Reseach, National Cancer Institute Frederick, National Institutes of Health, Frederick, MD 21702 1201, USA
    Blood 104:3276-84. 2004
    ..These results reveal novel pathways regulating NK cell biologic functions and provide a basis for the design of therapeutic agents that can regulate the function of NK cells within the innate immune response...
  9. ncbi request reprint The proinflammatory cytokine interleukin-18 alters multiple signaling pathways to inhibit natural killer cell death
    Deborah L Hodge
    Laboratory of Experimental Immunology, Center for Cancer Research, National Cancer Institute Frederick, Frederick, MD 21702 1201, USA
    J Interferon Cytokine Res 26:706-18. 2006
    ....